
Pharmacally
PDAC
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in PDAC
Clinical TrialsNovel Four-Drug Combination Shows Robust Activity Against Metastatic PDACChemo4METPANC phase 2 data show a 64% objective response rate and 91% disease control rate with motixafortide-based therapy in metastatic…Fact-Checked
Mergers & AcquisitionsIDEAYA and Genentech Partner to Evaluate IDE892 Plus GDC-7035 in PDACIDEAYA Biosciences and Genentech are collaborating to evaluate IDE892, an investigational MTA-cooperative PRMT5 inhibitor, with GDC-7035, Genentech’s KRAS G12D inhibitor, in patients with pancreatic ductal adenocarcinoma harboring both…Fact-Checked
Health TidingsIDEAYA Starts IDE892 Phase 1/2 Expansion in MTAP-Deleted PDAC and NSCLCIDEAYA Biosciences has initiated the Part 2 monotherapy expansion of its Phase 1/2 trial evaluating IDE892 in MTAP-deleted pancreatic ductal adenocarcinoma and non-small cell lung cancer.Fact-Checked
Health TidingsRevMed’s Daraxonrasib Cuts Death Risk by 60% in PDACDaraxonrasib achieved a 60% reduction in risk of death and doubled progression‑free survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.